U.S. markets open in 7 hours 24 minutes
  • S&P Futures

    3,698.00
    +28.00 (+0.76%)
     
  • Dow Futures

    29,537.00
    +194.00 (+0.66%)
     
  • Nasdaq Futures

    11,411.50
    +95.25 (+0.84%)
     
  • Russell 2000 Futures

    1,680.10
    +17.60 (+1.06%)
     
  • Crude Oil

    77.67
    +0.96 (+1.25%)
     
  • Gold

    1,642.80
    +9.40 (+0.58%)
     
  • Silver

    18.58
    +0.10 (+0.57%)
     
  • EUR/USD

    0.9655
    +0.0044 (+0.45%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    32.26
    +2.34 (+7.82%)
     
  • GBP/USD

    1.0819
    +0.0135 (+1.27%)
     
  • USD/JPY

    144.3690
    -0.3110 (-0.21%)
     
  • BTC-USD

    20,174.70
    +1,379.92 (+7.34%)
     
  • CMC Crypto 200

    461.16
    +28.06 (+6.48%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,542.71
    +111.16 (+0.42%)
     

McKesson (MCK) Stock Moves -1.06%: What You Should Know

·3 min read

In the latest trading session, McKesson (MCK) closed at $343.27, marking a -1.06% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.72%. Meanwhile, the Dow lost 1.62%, and the Nasdaq, a tech-heavy index, added 0.09%.

Prior to today's trading, shares of the prescription drug distributor had lost 5.43% over the past month. This has was narrower than the Medical sector's loss of 6.61% and the S&P 500's loss of 9.09% in that time.

Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. The company is expected to report EPS of $6.13, down 0.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $69.66 billion, up 4.64% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $24.42 per share and revenue of $276.88 billion, which would represent changes of +3.08% and +4.89%, respectively, from the prior year.

Any recent changes to analyst estimates for McKesson should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.11% higher. McKesson currently has a Zacks Rank of #2 (Buy).

Digging into valuation, McKesson currently has a Forward P/E ratio of 14.21. This valuation marks a discount compared to its industry's average Forward P/E of 17.59.

We can also see that MCK currently has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MCK's industry had an average PEG ratio of 1.9 as of yesterday's close.

The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 193, which puts it in the bottom 24% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow MCK in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
McKesson Corporation (MCK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research